10-Q: GT Biopharma Reports Q3 2024 Results, Advances TriKE Platform

GT Biopharma reported its financial results for the third quarter of 2024, highlighting progress in its TriKE platform development and clinical trial preparations.

Summary

• GT Biopharma, a clinical-stage biopharmaceutical company, released its financial results for the quarter ended September 30, 2024.
• The company reported a net loss of $3.4 million for the quarter and $9.4 million for the nine-month period.
• Research and development expenses were $1.3 million for the quarter and $3.9 million for the nine-month period.
• Selling, general, and administrative expenses were $2.3 million for the quarter and $6.7 million for the nine-month period.
• The company's cash and cash equivalents totaled $6.4 million as of September 30, 2024.
• GT Biopharma is focused on developing its TriKE and Dual Targeting TriKE platforms for cancer therapies.
• The company received FDA clearance for its Investigational New Drug (IND) application for GTB-3650 in late June 2024 and anticipates starting study enrollment in the second half of 2024.
• GTB-5550, a B7-H3 targeted TriKE, is progressing through preclinical studies with an IND submission expected in the first half of 2025.
• The company has a going concern warning due to operating losses and the need for additional financing.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While there is positive progress in clinical development with FDA clearance for GTB-3650 and advancement of GTB-5550, the significant net loss, going concern warning, and ongoing legal issues raise concerns. The need for additional financing is a significant risk.

Positives

• The company received FDA clearance for its IND application for GTB-3650, a significant milestone for the company.
• GTB-5550 is progressing through preclinical studies, indicating continued pipeline development.
• The company has a proprietary TriKE platform with potential for treating various cancers and autoimmune disorders.
• The company has cash and cash equivalents of $6.4 million.

Negatives

• The company reported a net loss of $9.4 million for the nine months ended September 30, 2024.
• The company has a going concern warning due to operating losses and the need for additional financing.
• The company's operating expenses are significant, with selling, general, and administrative expenses increasing by $3.0 million for the nine months ended September 30, 2024.
• The company has a history of operating losses since inception.

Risks

• The company's ability to continue as a going concern is dependent on securing additional financing.
• The company may be forced to delay, reduce, or eliminate discretionary spending if additional financing is not secured.
• The company is subject to risks associated with clinical trials and regulatory approvals.
• The company is involved in ongoing legal proceedings, including an arbitration demand against a former CFO and a lawsuit from a former interim CEO.
• The company has significant accounts payable to related parties, including Cytovance Biologics, Inc.

Future Outlook

The company anticipates starting study enrollment for GTB-3650 in the second half of 2024 and expects to submit an IND application for GTB-5550 in the first half of 2025. The company also expects its direct clinical and preclinical expenses to increase in the second half of 2024.

Management Comments

• The company is focused on the development and commercialization of novel immuno-oncology products based on our proprietary Tri-specific Killer Engager (TriKE), and Tetra-specific Killer Engager (Dual Targeting TriKE) fusion protein immune cell engager technology platforms.
• The company believes its TriKEs may have the ability, if approved for marketing, to be used as both monotherapy and in combination with other standard-of-care therapies.
• The company is moving GTB-3650 clinically based on pre-clinical data showing a marked increase in potency compared to GTB-3550, which we anticipate could lead to an enhanced efficacy signal in AML and MDS.
• The company anticipates approval to start study enrollment targeting patients with relapsed/refractory AML and high grade MDS in the second half of 2024.
• The initial trial expected in 2025 is designed as a basket trial for patients with B7-H3+ solid tumors using Monday through Friday dosing (2 weeks on and 2 weeks off to prevent immune exhaustion), and is dependent on manufacturing of clinical materials.

Industry Context

GT Biopharma is operating in the competitive immuno-oncology space, focusing on novel therapies that harness the power of natural killer cells. The company's TriKE platform represents a unique approach to cancer treatment, differentiating it from traditional antibody-based therapies and other cell-based immunotherapies. The company's focus on both hematological malignancies and solid tumors positions it to address a broad range of unmet medical needs.

Comparison to Industry Standards

• GT Biopharma's approach of using TriKE technology to engage natural killer cells is similar to other companies developing bispecific and trispecific antibodies, such as Amgen with its BiTE platform and Regeneron with its bispecific antibodies.
• However, GT Biopharma's TriKE platform is unique in its design, incorporating a modified form of IL-15 to enhance NK cell activity, which is different from the approaches used by other companies.
• The company's focus on camelid nanobody technology for its second-generation TriKEs is also a differentiating factor, potentially offering greater affinity and potency compared to traditional antibodies.
• Compared to companies like Kite Pharma and Juno Therapeutics, which focus on CAR T-cell therapies, GT Biopharma's approach is off-the-shelf and does not require patient-specific customization, potentially offering a more scalable and cost-effective solution.
• The company's financial results, with a net loss of $9.4 million for the nine months ended September 30, 2024, are typical for a clinical-stage biopharmaceutical company that is still in the development phase and has not yet generated revenue from product sales. This is comparable to other companies in the same stage of development, such as those in the early stages of clinical trials.

Legal Proceedings

• The company filed an AAA Arbitration Demand against Manu Ohri, its former Chief Financial Officer, for breach of fiduciary duties and breach of contract.
• Mr. Ohri filed a general denial and counterclaims for breach of his Employment Agreement and Separation Agreement.
• Former interim Chief Executive Officer, Dr. Gregory Berk, filed a lawsuit alleging discrimination and retaliation.
• The company has agreed to resolve the Berk matter and expects the lawsuit to be dismissed shortly.
• TWF Global, LLC filed a complaint against the company, which was voluntarily dismissed without prejudice.
• The company filed a Summons and Complaint for Interpleader against TWF and Z-One LLC, asking the Supreme Court to determine if the company's shares of common stock are properly registered to TWF or Z-One LLC.

Related Party Transactions

• The company has significant accounts payable to Cytovance Biologics, Inc., a related party, for biologic development and manufacturing services.
• The company made cash payments of $3.4 million and issued 127,597 shares of common stock to Cytovance to settle accounts payable during the nine months ended September 30, 2024.
• The company has ongoing research agreements with the University of Minnesota, with commitments for unbilled and unaccrued amounts.

Stakeholder Impact

• Shareholders face the risk of dilution if the company raises additional capital through equity offerings.
• Employees may be affected by potential delays, reductions, or eliminations in discretionary spending if the company does not secure additional financing.
• Customers and suppliers may be impacted by the company's financial instability and potential delays in product development.
• Creditors face the risk of non-payment if the company is unable to continue as a going concern.

Next Steps

• The company anticipates starting study enrollment for GTB-3650 in the second half of 2024.
• The company plans to complete the product development of GTB-5550 and anticipates submission of an IND application in the first half of 2025.
• The company will continue to seek additional financing to support its operations.

Key Dates

Keywords

TriKE, immuno-oncology, GTB-3650, GTB-5550, FDA, clinical trials, biopharmaceutical, cancer therapy, natural killer cells, IND, research and development, financial results